Tixagevimab/cilgavimab or placebo for COVID-19 in ACTIV-2: Safety, pharmacokinetics and neutralizing and anti-drug antibodies by Rachel A. Bender Ignacio, Kara W. Chew, Carlee Moser, Judith S. Currier, Joseph J. Eron, Arzhang Cyrus Javan, Mark J. Giganti, Justin Ritz, Michael Gibbs, Hervé Tchouakam Kouekam, Mark T. Esser, Eric S. Daar, Manish Choudhary, Rinki Deo, Courtney V. Fletcher, Jonathan Z. Li, Michael D. Hughes, Davey Smith, David Alain Wohl

Get full text

Frequency of non-communicable diseases in people 50 years of age and older receiving HIV care in Latin America. by Pablo F Belaunzaran-Zamudio, Yanink Caro-Vega, Mark J Giganti, Jessica L Castilho, Brenda E Crabtree-Ramirez, Bryan E Shepherd, Fernando Mejía, Carina Cesar, Rodrigo C Moreira, Marcelo Wolff, Jean W Pape, Denis Padgett, Catherine C McGowan, Juan G Sierra-Madero, Caribbean, Central and South American network for HIV epidemiology (CCASAnet)

Get full text